SNGX Logo

Soligenix, Inc. (SNGX) 

NASDAQ
Market Cap
$8.07M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
720 of 776
Rank in Industry
394 of 433

Largest Insider Buys in Sector

SNGX Stock Price History Chart

SNGX Stock Performance

About Soligenix, Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of …

Insider Activity of Soligenix, Inc.

Over the last 12 months, insiders at Soligenix, Inc. have bought $0 and sold $0 worth of Soligenix, Inc. stock.

On average, over the past 5 years, insiders at Soligenix, Inc. have bought $15,888 and sold $2,701 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 20,000 shares for transaction amount of $8,866 was made by SCHABER CHRISTOPHER J (CHAIRMAN, CEO AND PRESIDENT) on 2022‑05‑18.

List of Insider Buy and Sell Transactions, Soligenix, Inc.

2022-05-18PurchaseCHAIRMAN, CEO AND PRESIDENT
20,000
0.0466%
$0.44$8,866+23.81%
2022-05-18PurchaseSENIOR VICE PRESIDENT AND CMO
8,000
0.021%
$0.50$4,000+23.81%
2021-12-17PurchaseCHAIRMAN, CEO AND PRESIDENT
7,000
<0.0001%
$0.74$5,179-13.05%
2021-12-15PurchaseSenior Vice President and CFO
1,000
<0.0001%
$0.70$700-10.86%
2021-12-14PurchaseChairman, CEO and President
10,000
0.0001%
$0.73$7,269-7.05%
2021-12-14PurchaseSenior Vice President and CFO
10,000
0.0001%
$0.71$7,119-7.05%
2021-05-14Saledirector
3,000
<0.0001%
$0.90$2,701+1.43%
2021-05-14Purchasedirector
3,000
<0.0001%
$0.89$2,664+1.43%
2019-11-19PurchaseChairman, CEO and President
10,770
0.0544%
$0.93$10,016+92.63%
2019-11-19Purchasedirector
2,000
0.0101%
$0.93$1,850+92.63%
2019-09-23Purchasedirector
14,940
0.0003%
$0.93$13,870+95.33%
2019-09-19Purchasedirector
4,000
<0.0001%
$0.94$3,740+93.21%
2019-04-22PurchaseChairman, CEO and President
5,000
0.0001%
$0.72$3,577+47.89%
2019-04-22Purchasedirector
10,000
0.0002%
$0.73$7,274+47.89%
2018-10-18PurchaseChairman, CEO and President
8,700
0.0002%
$1.17$10,177-22.88%
2018-10-17Purchasedirector
170,000
0.0046%
$1.16$197,200-13.90%
2018-08-22PurchaseChairman, CEO and President
3,530
<0.0001%
$1.42$5,012-30.71%
2017-11-29Sale
16,416
0.0012%
$2.12$34,802-19.31%
2017-11-29Purchase
293,510
0.0223%
$2.12$622,241-19.31%
2017-05-08Sale10 percent owner
11,576
0.0009%
$2.54$29,403-16.86%

Insider Historical Profitability

62.23%
CAVAZZA PAOLO10 percent owner
54227816
2377.9749%
$3.5430
CAVAZZA CLAUDIO10 percent owner
54227816
2377.9749%
$3.5430
BAM Management LLC10 percent owner
21766092
954.4773%
$3.5411
Pearson Mark E.director
2500000
109.6289%
$3.5410
KANZER STEVE Hdirector
1282203
56.2266%
$3.5410

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.